文献速递心力衰竭与心肌病

曲美他嗪对非梗阻性肥厚型心肌病患者运动能力的影响:一项随机临床试验

Effect of Trimetazidine Dihydrochloride Therapy on Exercise Capacity in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2019-01-01

这项随机、安慰剂对照、双盲临床试验纳入51例有症状的非梗阻性肥厚型心肌病患者,评估口服曲美他嗪20mg每日三次治疗3个月对运动能力的影响。

要点

  • 曲美他嗪未改善非梗阻性肥厚型心肌病患者的运动能力。
  • 曲美他嗪组峰值耗氧量较安慰剂组显著降低。
  • 曲美他嗪组6分钟步行距离较安慰剂组缩短。

核心结论

  • 在有症状的非梗阻性肥厚型心肌病患者中,曲美他嗪治疗未改善运动能力。

研究设计与样本

  • 随机、安慰剂对照、双盲临床试验,在英国伦敦大学学院医院心脏医院进行。
  • 纳入51例药物难治性有症状(NYHA class ≥2)患者,年龄24至74岁,最大左心室流出道压力阶差≤50 mmHg,峰值耗氧量≤预测值的80%。
  • 参与者随机接受曲美他嗪20 mg每日三次(n=27)或安慰剂(n=24)治疗3个月。
  • 主要终点为直立自行车测力计期间的峰值耗氧量。

主要发现

  • 49例完成研究(曲美他嗪组n=26,安慰剂组n=23),34例(70%)为男性,平均(SD)年龄50(13)岁。
  • 曲美他嗪组3个月时6分钟步行距离较安慰剂组少38.4米(95%CI 5.13至71.70),经基线步行距离调整。

临床怎么用

  • 对于有症状的非梗阻性肥厚型心肌病患者,曲美他嗪不应用于改善运动能力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Hypertrophic cardiomyopathy causes limiting symptoms in patients, mediated partly through inefficient myocardial energy use. There is conflicting evidence for therapy with inhibitors of myocardial fatty acid metabolism in patients with nonobstructive hypertrophic cardiomyopathy. OBJECTIVE: To determine the effect of oral therapy with trimetazidine, a direct inhibitor of fatty acid β-oxidation, on exercise capacity in patients with symptomatic nonobstructive hypertrophic cardiomyopathy. DESIGN, SETTING, AND PARTICIPANTS: This randomized, placebo-controlled, double-blind clinical trial at The Heart Hospital, University College London Hospitals, London, United Kingdom was performed between May 31, 2012, and September 8, 2014. The trial included 51 drug-refractory symptomatic (New York Heart Association class ≥2) patients aged 24 to 74 years with a maximum left ventricular outflow tract gradient 50 mm Hg or lower and a peak oxygen consumption during exercise of 80% or less predicted value for age and sex. Statistical analysis was performed from March 1, 2016 through July 4, 2018. INTERVENTIONS: Participants were randomly assigned to trimetazidine, 20 mg, 3 times daily (n = 27) or placebo (n = 24) for 3 months. MAIN OUTCOMES AND MEASURES: The primary end point was peak oxygen consumption during upright bicycle ergometry. Secondary end points were 6-minute walk distance, quality of life (Minnesota Living with Heart Failure questionnaire), frequency of ventricular ectopic beats, diastolic function, serum N-terminal pro-brain natriuretic peptide level, and troponin T level. RESULTS: Of 49 participants who received trimetazidine (n = 26) or placebo (n = 23) and completed the study, 34 (70%) were male; the mean (SD) age was 50 (13) years. Trimetazidine therapy did not improve exercise capacity, with patients in the trimetazidine group walking 38.4 m (95% CI, 5.13 to 71.70 m) less than patients in the placebo group at 3 months after adjustment for their baseline walking distance measurements. After adjustment for baseline values, peak oxygen consumption was 1.35 mL/kg per minute lower (95% CI, -2.58 to -0.11 mL/kg per minute; P = .03) in the intervention group after 3 months. CONCLUSIONS AND RELEVANCE: In symptomatic patients with nonobstructive hypertrophic cardiomyopathy, trimetazidine therapy does not improve exercise capacity. Pharmacologic therapy for this disease remains limited. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01696370.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Coats CJ, Pavlou M, Watkinson OT, et al. Effect of Trimetazidine Dihydrochloride Therapy on Exercise Capacity in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Clinical Trial. JAMA Cardiol. 2019. PMID: 30725091. doi:10.1001/jamacardio.2018.4847

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。